A randomized trial of empagliflozin to increase plasma sodium levels in patients with the syndrome of inappropriate antidiuresis
Journal of the American Society of Nephrology Feb 10, 2020
Refardt J, Imber C, Sailer CO, et al. - Researchers investigated the efficacy of empagliflozin [sodium glucose cotransporter 2 inhibitor] to treat the syndrome of inappropriate antidiuresis (SIAD), by performing this double-blind, randomized trial. Participants were 88 hospitalized patients with SIAD-induced hyponatremia < 130 mmol/L and these patients were allocated to receive, in addition to standard fluid restriction of < 1000 ml/24 h, a once-daily dose of oral empagliflozin or placebo for 4 days. Findings revealed a larger increase in plasma sodium levels among patients treated with empagliflozin vs those who received placebo in this study sample of hospitalized patients with SIAD managed with fluid restriction.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries